Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.11.6619

High Resolution Melting Analysis for Epidermal Growth Factor Receptor Mutations in Formalin-fixed Paraffin-embedded Tissue and Plasma Free DNA from Non-small Cell Lung Cancer Patients  

Jing, Chang-Wen (Clinical Cancer Research Center, Jiangsu Cancer Hospical)
Wang, Zhuo (Clinical Cancer Research Center, Jiangsu Cancer Hospical)
Cao, Hai-Xia (Department of Epidemiology, Jiangsu Cancer Hospical)
Ma, Rong (Clinical Cancer Research Center, Jiangsu Cancer Hospical)
Wu, Jian-Zhong (Clinical Cancer Research Center, Jiangsu Cancer Hospical)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.11, 2013 , pp. 6619-6623 More about this Journal
Abstract
Background:The aim of the research was to explore a cost effective, fast, easy to perform, and sensitive method for epidermal growth factor receptor (EGFR) mutation testing. Methods: High resolution melting analysis (HRM) was introduced to evaluate the efficacy of the analysis for dectecting EGFR mutations in exons 18 to 21 using formalin-fixed paraffin-embedded (FFPE) tissues and plasma free DNA from 120 patients. Results: The total EGFR mutation rate was 37.5% (45/120) detected by direct sequencing. There were 48 mutations in 120 FFPE tissues assessed by HRM. For plasma free DNA, the EGFR mutation rate was 25.8% (31/120). The sensitivity of HRM assays in FFPE samples was 100% by HRM. There was a low false-positive mutation rate but a high false-negative rate in plasma free DNA detected by HRM. Conclusions: Our results show that HRM analysis has the advantage of small tumor sample need. HRM applied with plasma free DNA showed a high false-negative rate but a low false-positive rate. Further research into appropriate methods and analysis needs to be performed before HRM for plasma free DNA could be accepted as an option in diagnostic or screening settings.
Keywords
EGFR mutation; high resolution melting analysis; plasma free DNA; non-small cell lung cancer;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Do H, Krypuy M, Mitchell PL, et al (2008). High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer, 8, 142.   DOI   ScienceOn
2 Goto K, Ichinose Y, Ohe Y, et al (2012). Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol, 7, 115-21.   DOI
3 Govindan R, Page N, Morgensztern D, et al (2006). Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 24, 4539-44.   DOI   ScienceOn
4 Hu C, Liu X, Chen Y, et al (2012). Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis. Oncol Rep, 28, 1815-21.   DOI
5 Jian G, Songwen Z, Ling Z, et al (2010). Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. J Cancer Res Clin Oncol, 136, 1341-7.   DOI   ScienceOn
6 Jiang B, Liu F, Yang L, et al (2011). Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer. J Int Med Res, 39, 1392-401.   DOI
7 Kim HR, Lee SY, Hyun DS, et al (2013). Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping. J Exp Clin Cancer Res, 32, 50.   DOI   ScienceOn
8 Kimura H, Kasahara K, Kawaishi M, et al (2006a). Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res, 12, 3915-21.   DOI   ScienceOn
9 Kimura H, Kasahara K, Shibata K, et al (2006b). EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer. J Thorac Oncol, 1, 260-7.   DOI
10 Krypuy M, Ahmed AA, Etemadmoghadam D, et al (2007). High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer, 7, 168.   DOI
11 Kuang Y, Rogers A, Yeap BY, et al (2009). Non-invasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res, 15, 2630-6.   DOI   ScienceOn
12 Mack PC, Holland WS, Burich RA, et al (2009). EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol, 4, 1466-72.   DOI
13 Maemondo M, Inoue A, Kobayashi K, et al (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 362, 2380-8.   DOI   ScienceOn
14 Nomoto K, Tsuta K, Takano T, et al (2006). Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol, 126, 608-15.   DOI   ScienceOn
15 Maheswaran S, Sequist LV, Nagrath S, et al (2008). Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med, 359, 366-77.   DOI   ScienceOn
16 Mitsudomi T, Morita S, Yatabe Y, et al (2010). Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 11, 121-8.   DOI   ScienceOn
17 Nicholson RI, Gee JM, Harper ME. (2001). EGFR and cancer prognosis. Eur J Cancer, 37 Suppl 4, S9-15.
18 Pathak AK, Bhutani M, Kumar S, et al (2006). Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem, 52, 1833-42.
19 Scaltriti M and Baselga J (2006). The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res, 12, 5268-72.   DOI   ScienceOn
20 Shigematsu H, Lin L, Takahashi T, et al (2005). Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst, 97, 339-46.   DOI   ScienceOn
21 Sozzi G, Conte D, Leon M, et al (2003). Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol, 21, 3902-8.   DOI   ScienceOn
22 Takano EA, Mitchell G, Fox S B, et al (2008). Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis. BMC Cancer, 8, 59.   DOI   ScienceOn
23 Zhou C, Wu YL, Chen G, et al (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 12, 735-42.   DOI   ScienceOn
24 Thatcher N, Chang A, Parikh P, et al (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 366, 1527-37.   DOI   ScienceOn
25 Wojdacz TK, Dobrovic A (2007). Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res, 35, e41.   DOI   ScienceOn